Health Condition 1: null- Kasa (Stable Chronic Bronchitis)
Conditions
Interventions
Intervention1: Talisadi Churna: Reference AFI I 7:13 API II Vol I
Dosage 3 gm TDS with honey after food
Control Intervention1: Not Applicable: Not Applicable
Sponsors
Central Council for Research in Ayurvedic Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1 Patients of chronic stable bronchitis suffering from minimum of two years.(Chronic bronchitis is defined clinically as chronic Productive cough for 3 months in each of 2 successive years in that patient in whom other causes of productive cough have been excluded) 2 Stable symptoms for the past 2 weeks i.e. unchanged amount & colour of daily sputum 3 FEV1 > 80% 4 Patient willing and able to participate in the study for 16 weeks
Exclusion criteria
Exclusion criteria: 1.Any other pulmonary diagnosis like Emphysema, Cor pulmonale, Cyanosis, Pneumonia, Asthma, Cystic fibrosis, Tuberculosis, Lung cancer etc. 2.Patients of Diabetes Mellitus 3.Patients with poorly controlled Hypertension (equal or more than 160 / 100 mmHg). 4.Patients on prolonged ( > 6 weeks) medication with corticosteroids, bronchodilators, Mast cell stabilizers, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study. 5.Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal disorders etc). 6.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 7.Symptomatic patients with clinical evidence of Heart failure. 8.Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL). 9.Smokers/alcoholics and/or drug abusers. 10.Patients who have completed participation in any other clinical trial during the past six (06) months. 11.Any other condition which the Investigator thinks may jeopardize the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1 Change in Leicester Cough Questionnaire (LCQ) Scores. 2 Number of patients who did not have any episode of acute exacerbation from baseline to end point. Timepoint: At baseline During Treatment (After Every 14 days) At the end of treatment After follow up of 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 Quality of life outcome from St. Georgeâ??s Respiratory Questionnaire (SGRQ) Score. 2 Functional Exercise capacity 3 Any adverse Events Timepoint: At baseline During Treatment (After Every 14 days) At the end of treatment After follow up of 4 weeks | — |
Countries
India
Contacts
Public ContactDr Rinku Tomar
Central Ayurveda Research Institute for Respiratory Disorders
Outcome results
None listed